Salīdzināt metodes

	MelasQoL (Melasmas dzīves kvalitātes skala)	POEM (Pacientu novērtējuma ekzēmas skala)	Skindex-29 (Ādas slimību dzīves kvalitātes novērtēšanas instruments)
Nozare	Dermatoloģija	Dermatoloģija	Dermatoloģija
Saime	Process / pipeline	Process / pipeline	Process / pipeline
Izcelsmes gads	2006	2004	1997
Autors	Cestari TF, Hexsel D	Charman CR, Venn AJ, Williams HC	Chren MM, Lasek RJ
Tips	Self-report	Self-report	Self-report
Pirmavots	Cestari TF, Hexsel D, Brandt FS, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL. Br J Dermatol. 2006;156(Suppl 3):13-20.	Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519.	Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713.
Citi nosaukumi	Melasma-QoL	POEM Score	Skindex, Skindex-QoL
Saistītās	3	2	1
Kopsavilkums	MelasQoL is a disease-specific, patient-administered quality-of-life measure designed to assess the psychosocial burden of melasma, a common chronic disorder of symmetric facial hyperpigmentation. Developed by Cestari and colleagues in 2006, it captures the unique emotional and social impacts of a predominantly cosmetic condition that disproportionately affects women of color. MelasQoL is essential in clinical trials and observational studies of melasma treatments to ensure that efficacy encompasses meaningful quality-of-life outcomes.	The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care.	Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes.